Hope S. Rugo

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events

  npj Breast Cancer · 2026-06-26

• Comparison of survival outcomes for people with HR+/HER2− metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary

  Future Oncology · 2026-06-21

• RISE UP for breast cancer 2024: conference highlights & takeaways

  Breast Cancer Research and Treatment · 2026-01-01 · 1 citations

• KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy

  Clinical Cancer Research · 2025-12-17

• Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

  Nature Communications · 2025-12-09 · 6 citations

• Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

  npj Breast Cancer · 2025-12-04 · 4 citations

• Multicenter Interspecialty Consensus on Experimental Oncology Drug–Related Ocular Adverse Event Reporting

  JAMA Ophthalmology · 2025-12-04 · 5 citations

• Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer

  npj Breast Cancer · 2025-12-03 · 1 citations

• Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies

  The Oncologist · 2025-11-28 · 3 citations

• Supplementary Figure 8 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 4 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 6 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 5 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 3 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 2 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 1 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 9 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Supplementary Figure 7 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma

  2025-11-25

• Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer

  npj Breast Cancer · 2025-11-21 · 1 citations

• Real-World Outcomes of Elacestrant in ER+, HER2−, <i>ESR1</i> -Mutant Metastatic Breast Cancer

  Clinical Cancer Research · 2025-11-13 · 7 citations